Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. EMA (2017) Rydapt. https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt. Accessed 25 Apr 2023
2. FDA (2021) RYDAPT® (midostaurin) capsules, for oral use Initial US. Approval: 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207997s008lbledt.pdf. Accessed 09 Sep 2023
3. Gu H, Dutreix C, Rebello S, Ouatas T, Wang L, Chun DY, Einolf HJ, He H (2018) Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin. Drug Metab Dispos 46(2):109–121. https://doi.org/10.1124/dmd.117.078006
4. He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K, Heimbach T (2017) Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos 45(5):540–555. https://doi.org/10.1124/dmd.116.072744
5. Nordt SP, Clark RF (1997) Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 15(3):357–365. https://doi.org/10.1016/S0736-4679(97)00022-X
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献